From the company's website regarding Hepatitis C in-house pipeline....
"We believe that completing this work will provide us with valuable data that supports our ddRNAi technology platform and other pipeline programs."
The only other data that they really haven't released is efficacy in the truest sense...some kind of viral load effect. Otherwise, what other data would they release that would be new?
- Forums
- ASX - By Stock
- Panno speaks on recent changes
From the company's website regarding Hepatitis C in-house...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)